In this study, we aimed to identify common or shared targets of BcR-signaling kinases as better biomarkers of aggressive CLL and potential targets to reverse drug resistance using a gene co-expression network analysis. This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.